Barclays lowered the firm’s price target on Clarivate to $5 from $6 and keeps an Underweight rating on the shares. The company’s Q2 results and lowered fiscal year organic guide once again disappointed investors, the analyst tells investors in a research note. The firm says the results and CEO change are a negative read near-term for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLVT: